Therefore, targeting the CD27/CD70 signaling pathway or CD70-expressing malignant cells using CAR-T-cell therapy or antibodies represents a promising strategy for therapeutic intervention to address T cell exhaustion and suppression in MCL.58 The gene discussed is CD27; the disease is mantle cell lymphoma.